After the "cancer king" broke

2026-11-14 22:51

Reads:


Five weeks, $198million.


In the first commercial quarter after the launch of a back-line pancreatic cancer drug, only five weeks were counted, and the judgment of the market on the unmet demand was written into the sales figures.


In August 2026, daraxonrasib, a KRAS inhibitor, was approved by FDA. In its first commercialization quarter, it recorded a net product revenue of 198million US dollars and treated more than 5000 US patients, higher than analysts' previous expectations of 80million to 100million US dollars for the first quarter. In the first half of the month of approval, Baiji Shenzhou won the rights and interests of the product in some Asian markets and promoted it to enter the domestic priority review channel.


The explosive power of the back line no longer needs to be proved, but this race is far more than a winner take all story.
According to the data, there are more than 40 KRAS G12D inhibitors in the global clinical stage, and only three of them have entered phase III; More than 20 pipelines in Pan Ras direction are in parallel at the clinical stage. The KRAS family as a whole has gathered nearly 40 sponsors, dozens of drugs and hundreds of trials.


From selective G12D to pan RAS, from molecular glue to degrader, the technical route has not yet converged, but the competition density has been full.

 


01、Five weeks and 5000 patients


About a month after its launch, the initial sales performance of daraxonrasib, a ras inhibitor of revolution medicines, was described as "amazing" by many analysis institutions. The high expectations of the market for the drug were being fulfilled.


According to the information disclosed by the company, daraxonrasib (trade name rasonque) achieved sales of US $197.6 million in the third quarter as of September 30 after it was approved for the treatment of patients with pancreatic adenocarcinoma.


Analysts' comments are quite direct. Leerink partners said that revolution medicines "is completing the marketing of the best oncology drugs so far". Jefferies said that sales were "even more than twice the most optimistic expectation", and it was predicted to reach $527million in the fourth quarter. Evercore ISI said its debut was amazing. It is expected to sell US $500million in the fourth quarter, and it is estimated that the whole year of 2027 will be about US $2.8 billion.


Although the sales performance was positive, revolution medicines remained cautious about the future potential of daraxonrasib. The company said that it had been commercialized for only five weeks, and it was still difficult to judge the track of listing normalization; Expanding accessibility transition and waiting for patients before approval belong to "limited early listing dynamics", which are also the main driving forces of current large-scale. As the listing matures, the revenue will more reflect the continuous treatment and medication duration of new eligible patients.


In five weeks, more than 5000 patients in the United States have been treated. The above spokesperson classified the needs into three categories: Patients transitioning from the expansion of accessibility project, a considerable group of patients who had exhausted treatment options when approved, waiting for a new scheme, and eligible patients who started daraxonrasib after approval.


Early listing factors boosted daraxonrasib's debut, but analysts are still relatively confident in its long-term sales performance. Leerink estimated that the group of patients newly entering the second-line treatment and using daraxonrasib in the third quarter was also strong. Jefferies held a similar view. He admitted that the drug was concentrated in a large amount in the early stage, but he was still optimistic about the "organic demand" of the drug. He believed that the strong science, transformative efficacy, high unmet demand and the successful implementation of revolution medicines made daraxonrasib have the potential to become "one of the most successful drugs in the history of marketing".


Outside the United States, revolution medicines is still preparing for the launch of daraxonrasib in the European Union. The drug has been approved by the European Medicines Agency in October. The company is waiting for the official approval of the European Commission. The launch preparation and reimbursement work in various countries are advancing simultaneously. In addition, daraxonrasib was also subject to regulatory review in Japan.

 


02. Why can we sell so much


To answer why the first quarter revenue can reach this level, we need to see what kind of treatment space daraxonrasib has entered.


In the previous decades, the second-line treatment of metastatic pancreatic ductal adenocarcinoma was an area of repeated setbacks in drug development. Before 2013, the pooled analysis of multiple second-line clinical studies showed that the median progression free survival was about 2.9 months, the median overall survival was about 6 months, and the median remission rate was 23%. There was no improvement trend in more than a decade. After that, the chemotherapy regimen that entered the clinic pushed the median OS of the second-line to about 9 months, and the rise of the treatment ceiling was limited.


In addition, more than 90% of tumors in pancreatic cancer carry KRAS mutations, and the G12D subtype accounts for about 40%. Targeted drugs targeting this mutation family are absent for a long time. G12C inhibitor opened the first gap of KRAS drug in non-small cell lung cancer, while the mutation frequency of G12C in pancreatic cancer is only 1% to 2%, and this gap has little substantial coverage for the pancreatic cancer patient population.


Daraxonrasib takes the nature of this coverage one step further. The phase III trial rasolute 302 enrolled 500 patients with treated metastatic pancreatic ductal adenocarcinoma. The median overall survival was 13.2 months in daraxonrasib group and 6.7 months in chemotherapy group, with a hazard ratio of 0.40; The median progression free survival was 7.2 months versus 3.6 months; The objective response rate was about 32% vs 11%.


At ASCO's 2026 meeting, this set of data received a standing ovation. The discussion guests described it as the "previously unseen" survival improvement in pancreatic ductal adenocarcinoma trials.


The median OS of ITT population at 13.2 months, compared with the historical baseline of previous second-line chemotherapy for about 6 months, marked the significant shift of one-time treatment benchmark. The risk of death is relatively reduced by about 60%, which makes posterior line pancreatic cancer a highly promising targeting option with practice changing potential. However, the final establishment of this judgment remains to be tested by longer follow-up and more mature data.


FDA's review rhythm provides time conditions for this large-scale review. Daraxonrasib was approved through the framework of project ORBIS, with the participation of Health Canada, and the participation of EMA and Japan PMDA as observers. The real-time tumor review pilot project will advance the final approval time by about 6.5 months compared with the FDA target date.


This fact can be translated into the prescribing behavior of 5000 patients in a quarter, also because the drug design it relies on solves a structural limitation of Ras targeting previously.


The first generation of KRAS G12C inhibitors targeted the GDP bound (inactive) state of RAS, and the inhibition was weakened after Ras was switched to the GTP bound active state. Daraxonrasib acts directly on the RAS active state through the mechanism of cyclophilin A-mediated ternary complex, and does not depend on specific mutated residues. This mechanism allows it to retain activity in G12, G13, q61 and other different Ras mutant variants as well as wild-type ras. The enrollment of phase III trials also did not set mutation specific screening.


From a commercial perspective, daraxonrasib's label covers a much wider population than any single mutation selective drug, and the vast majority of Ras driven tumors in second-line pancreatic cancer fall within its potential benefit range.

 


03. After the benchmark is erected


After the benchmark of second-line pancreatic cancer was moved by daraxonrasib, this change was soon transmitted from the sales figures in the US market to the global registration and commercialization pattern.


In August, Baiji Shenzhou introduced four RAS (on) inhibitors including daraxonrasib from revolution medicine to develop and commercialize their rights in specific Asian markets (excluding Japan and South Korea), and the pace of subsequent domestic landing was quite compact.


According to the announcement of CDE on November 9, daraxonrasib tablets are to be included in the priority review, and the proposed indications are consistent with the scope of FDA approval, covering adult patients with metastatic pancreatic cancer who have received at least one previous systemic therapy or are not suitable for multi-agent systemic therapy. According to the standard timeline of priority review, the time window for domestic approval may fall near the middle of 2027.


Daraxonrasib is the world's first broad-spectrum Ras targeted drug that has completed phase III validation and been approved. What Baiji has obtained is a benchmark asset that has run through the core registration path in the United States. However, there is a long-term lack of targeted options for post-line treatment of pancreatic cancer in China. The priority review channel provides a predictable filling rhythm for this gap.


The density of Chinese pipelines in this round of Ras competition is hard to see in the G12C era five years ago.


Hengrui's hrs-4642 has been registered in phase III clinical practice for perioperative pancreatic cancer, and is the world's first KRAS G12D inhibitor to enter phase III under this indication scenario; In its phase II perioperative study, tumor shrinkage was observed in all 60 resectable patients.


Gab-23e73, a pan KRAS inhibitor of gakos, reached an authorized cooperation with AstraZeneca at the end of 2025, with an initial payment of US $100million. Phase ib/iii of first-line pancreatic cancer has been started.


Gfh375 of JinFang is one step ahead of the second-line pancreatic cancer single agent registration phase III of oral G12D inhibitor, and covers the pan Ras direction with gfh276 and coupling route.


These pipelines are distributed in G12D selectivity, pan KRAS and pan RAS (on) and other different mechanisms, and the promotion rhythm is not completely synchronized, but on the whole, China has been pushed from the following position of Ras track to the synchronous interval of registered clinical.


Globally, the focus of competition is shifting from the back line to the front line, and from single drug to joint strategy. Incb161734, a KRAS G12D inhibitor of Incyte, was confirmed to have an orr of 81% and a 6-month PFS rate of 90% in patients with first-line combined mfolfirinox. The president of Incyte described it as "neck and neck" with zoldonrasib of revolution medicine.


The orr of zoldonrasib of revolution medicines in the front-line combined with mfolfirinox was 82%. The early data of two G12D selective drugs in the front-line combined chemotherapy scenario formed a referential parallel signal. The extension of daraxonrasib to the first-line is also advancing. Rasolute 303 research covers the first-line metastatic pancreatic cancer. The early signal relying on GNP chemotherapy has entered the phase III validation stage.


The number of patients with first-line pancreatic cancer is much larger than that of the back line. If the joint scheme can reproduce the magnitude of the back line at the front line, the commercial space of RAS (on) inhibition will not be defined within the framework of the back line.

 


- Conclusion -


Daraxonrasib's median OS of 13.2 months and hazard ratio of 0.40 established in the second line are becoming a reference that cannot be bypassed when subsequent drugs enter the same treatment space. If the latecomers seek the approval of the back-line acceleration only based on the single arm remission rate, it will be more difficult to obtain the equivalent position in the clinical adoption and payment negotiations than in the past.


Competition therefore converges in two more specific directions. The coverage width determines the size of the accessible population, the depth of the combination strategy determines how much incremental benefit can be superimposed on the front-line chemotherapy skeleton, and the safety and convenience of administration will determine the actual boundary of the treatment window in the long-term medication and combination scenarios.


The benchmark of second-line pancreatic cancer has been moved. How will the next stage of the track be shaped?
The sales figures on the back line are brilliant. What really determines the space is whether the activity can be replicated to a larger population and on a larger scale.


From November 19 to 21, the 2026 China Pharmaceutical City grand health industry forum hosted by Taizhou Municipal People's government will be held in Taizhou. With the theme of "bio manufacturing empowers great health, innovation and integration lead to a new future", the forum adopts a "1+6+1" architecture. Among them, the topic of "precision diagnosis and diagnostic reagent innovation" will focus on ras therapy, and bring together the government, industry, University, research and financial institutions to jointly dismantle the engineering proposition from laboratory to production line.


Reference article:
1. Hengrui KRAS G12D inhibitor started a new phase III clinical trial; Dingxiangyuan insight database
2 RevMed’s Rasonque debut nets ‘eye-popping’ $198M in 5 weeks, even as exec tempers expectations; fiercepharma
3. Daraxonrasib, a new drug for pancreatic cancer, is to be included in the priority review in China; Medicine cube info

Related News

Contact us

Address:Room 62, 6th Floor, Building 1, Zone 1, No.186 South 4th Ring West Road , Fengtai District, Beijing

Tel:010-83634390

Address:Address:Room 1704, Building E, Nanotechnology Park, SIP, Suzhou, Jiangsu Province

TONACEA

TONACEA

XIEYI Release

TONACEA

TONACEA Biotech

TONACEA

TONACEA Micro Service

TONACEA

©2022 TONACEA(beijing)Technology Development Co., Ltd

xueqiu.com zhihu.com MicroBlog